Conjugation site characterization of antibody–drug conjugates using electron-transfer/higher-energy collision dissociation (EThcD)
Analytica Chimica Acta · 2023
DOI: 10.1016/j.aca.2023.340978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytica Chimica Acta, 2023. Verfasst von Yuanli Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Analytical Research Center for Organic and Biological Molecules, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shan…. Hauptthemen laut MEDLINE: Immunoconjugates. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China Department of Science and Technology for Social Development, Shanghai Municipality Science and Technology Commission, National Key Research and Development Program of China.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) are formed by binding of cytotoxic drugs to monoclonal antibodies (mAbs) through chemical linkers. A comprehensive evaluation of the critical quality attributes (CQAs) of ADCs is vital for drug development but remains challenging owing to ADC structural heterogeneity than mAbs. Drug conjugation sites can considerably affect ADC properties, such as stability and pharmacokinetics, however, few studies have focused on method development in this area owing to technical challenges. Hybrid electron-transfer/higher-energy collision dissociation (EThcD) produces more fragment ions than conventional higher-energy collision dissociation (HCD) fragmentation, which aids in identifying and localizing post-translational modifications. Herein, we systematically employ EThcD to assess the fragmentation mode impact on conjugation site characterization for randomly conjugated and site-specific ADCs. EThcD generates more fragment ions in tandem mass spectrometry (MS/MS) spectra compared with HCD. Additional ions aid in pinpointing the correct conjugation sites that bear complex linker payload structures. Our study may contribute to the quality control of various preclinical and clinical ADCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Analytical Research Center for Organic and Biological Molecules, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Media, Chinese Academy of Sciences, Shanghai…
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai Institute for Food and Drug Control, 1500 Zhangheng Road, Shanghai, 201203, China. Electronic address: shaohong@smda.sh.cn.
Förderung
- Ministry of Science and Technology of the People's Republic of China Department of Science and Technology for Social Development
- Shanghai Municipality Science and Technology Commission
- National Key Research and Development Program of China
- Chinese Academy of Sciences
- Center for Medical Device Standardization Administration NMPA
Zitieren
APA
Song, Y., Gao, J., Meng, Q., Tang, F., Wang, Y., Zeng, Y., Huang, W., Shao, H., & Zhou, H. (2023). Conjugation site characterization of antibody–drug conjugates using electron-transfer/higher-energy collision dissociation (EThcD). Analytica Chimica Acta. https://doi.org/10.1016/j.aca.2023.340978
Vancouver
Song Y, Gao J, Meng Q, Tang F, Wang Y, Zeng Y, et al. Conjugation site characterization of antibody–drug conjugates using electron-transfer/higher-energy collision dissociation (EThcD). Analytica Chimica Acta. 2023. doi:10.1016/j.aca.2023.340978
BibTeX
@article{Song2023,
author = {Song, Yuanli and Gao, Jing and Meng, Qian and Tang, Feng and Wang, Yuqiu and Zeng, Yue and Huang, Wei and Shao, Hong and Zhou, Hu},
title = {Conjugation site characterization of antibody–drug conjugates using electron-transfer/higher-energy collision dissociation (EThcD)},
journal = {Analytica Chimica Acta},
year = {2023},
doi = {10.1016/j.aca.2023.340978}
}
EUVIMED